<DOC>
	<DOCNO>NCT00369759</DOCNO>
	<brief_summary>The primary objective study describe incidence RSV-associated LRI among infant &lt; 1 year age present ED select shoulder month .</brief_summary>
	<brief_title>An Epidemiological Study Evaluate RSV-Associated Lower Respiratory Track Infections Infants</brief_title>
	<detailed_description>- The primary objective study describe incidence RSV-associated LRI apnea ( % RSV positive ) among infant &lt; 1 year age present ED select shoulder month . The total number event also describe . - To characterize clinical outcome demographic data infant present ED RSV-associated LRI apnea - To characterize social burden ( form number day lose work parent/ guardian ) infants 14 day index ED visit hospital discharge also describe . - Based sample case collect cohort patient enrol near peak RSV disease traditional season , comparison rate RSV shoulder peak period describe . - To describe overall rate RSV-associated LRI apnea base general ED statistic collect entire study period .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>Written inform consent parent/guardian participate study Male female infant &lt; 1 year age ( child must enter his/her 1st birthday ) Physician diagnosis either ) acute LRI b ) apnea : A ) Acute LRI , define : 1 . Medical diagnosis bronchiolitis pneumonia , 2 . In absence either diagnosis , LRI determine investigator review medical record must include least one following : Retractions Wheezing Rales crackle The presence new infiltrate , chest Xray available , must diagnose ED physician radiologist B ) Apnea , define either : 1 . Cessation breathe &gt; 20 second history observation , 2 . Cessation breathe length time accompany cyanosis pallor , bradycardia detect monitor , 3 . ED primary diagnosis apnea Parent/guardian ability willingness available followup interview telephone Use palivizumab RSVIGIV time prior enrollment Participation trial investigational RSV prophylaxis therapeutic agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Acute Lower Respiratory Infection</keyword>
	<keyword>Retractions</keyword>
	<keyword>Bronchiolitis pneumonia</keyword>
	<keyword>Wheezing</keyword>
	<keyword>Rales</keyword>
	<keyword>Crackles</keyword>
</DOC>